Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS (sotorasib), a KRASG12C Inhibitor

2021年09月17日 09:55:07 来自: (0)参与

Combination of leading SOS1::pan-KRAS inhibitor with the first US FDA approved KRASG12C inhibitor has the potential to demonstrate additional therapeutic benefit for people living with KRAS G12C mutated cancers
The new clinical partnership adds to Boehringer Ingelheim’s comprehensive program investigating combinations of its SOS1::pan-KRAS inhibitor, BI 1701963 with potentially synergistic approaches

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced a clinical phase I collaboration with Amgen to evaluate the combination of BI 1701963, the first and most advanced SOS1::pan-KRAS inhibitor exhibiting activity against a broad spectrum of KRAS alleles, and LUMAKRAS™ (sotorasib), the first US Food and Drug Administration (FDA) approved KRASG12C inhibitor for adult patients with locally advanced or metastatic non-small cell lung cancer. The trial will investigate potential synergistic effects of this combination, possibly improving therapeutic outcomes beyond those of KRASG12C inhibitor therapy alone, specifically for people living with lung and colorectal cancers.

Preclinical data suggest that the combination of a KRASG12C inhibitor with a SOS1::pan-KRAS inhibitor may result in increased anti-tumor activity in KRAS G12C-driven cancers based on the complementary mechanisms of these targeted oncology agents.1 2 By shifting the equilibrium from active KRAS towards the inactive form, SOS1::pan-KRAS inhibitors have the potential to sensitize KRAS G12C-mutant tumors to covalent KRASG12C inhibitors that bind to inactive KRAS. In addition, SOS1 inhibitors block feedback reactivation which occurs upon pathway inhibition.

“We are excited to partner with Amgen, who have pioneered KRAS G12C inhibition, and to further expand our program to make a difference for people living with KRAS-driven cancers,” said Francesco Di Marco, Ph.D., Corporate Senior Vice President, Global Therapy Area Head Oncology at Boehringer Ingelheim. “Boehringer Ingelheim follows an ‘all-in’ research approach to taking cancer on, including the first and most advanced SOS1::pan-KRAS inhibitor which we investigate in several combinations and cancer types to realize even more opportunities to deliver potential therapeutic benefits to cancer patients.”

Under the terms of the non-exclusive collaboration, Amgen will be the sponsor of the trial and Boehringer Ingelheim and Amgen will jointly share the costs of and oversee clinical development for the combined therapy.

About BI 1701963
BI 1701963 is an investigational, orally available small molecule, that binds to the catalytic domain of SOS1 preventing the interaction with inactive KRAS. This reduces the formation of active KRAS and in consequence inhibits MAPK pathway signaling in KRAS-dependent cancers. SOS1 inhibition also simultaneously blocks feedback driven reactivation of the MAPK pathway. The selective inhibition of SOS1 is a therapeutic concept that could allow KRAS blockade irrespective of KRAS mutation type (pan-KRAS approach). SOS1::KRAS inhibitors exhibit activity on a broad spectrum of KRAS alleles, including all major G12D/V/C and G13D oncoproteins, as published by Hofmann MH, et al. in Cancer Discovery, a journal of the American Association of Cancer Research (AACR). BI 1701963 is currently being evaluated in phase I clinical trials in patients with advanced KRAS-mutated cancers to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties, and preliminary efficacy of BI 1701963 alone and in combination with MEK inhibitors, KRASG12C inhibitors or irinotecan.

Boehringer Ingelheim’s Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/clinical-collaboration-amgen

相关新闻
其它网友:只傷身不傷心
评论:如果有人和你说:不要脸。你可以对他说:对你根本不需要有脸!

天猫网友:夠鐘死心孒
评论:真正的爱情,不是一见钟情,而是日久生情 人人都说我很听话,其实我只听自己的话。

天涯网友:碎梦 3/3dream°
评论:每当我找到了成功的钥匙,就有人把锁给换了。

腾讯网友:不三姑娘 #
评论:有些人,认真的让你心疼,有些人,欠扁的让你牙疼

百度网友:谢谢你给的痛
评论:你那么喜欢劈腿,怎么不去跳芭蕾舞。

凤凰网友:为了她放弃她
评论:出门顶个避雷针,从此装B再也不怕遭雷劈!

猫扑网友:THOMAS 《死亡诗社》
评论:昨天去市里参加放鸽子比赛,结果就我一个人去了。

淘宝网友:夏花一般绚烂
评论:向上爬时,对遇到的人好点,因为掉下来时,你还会遇到他们。

搜狐网友:红颜负流年
评论:世界上最最废话的就是那句写在烟盒上面的“吸烟有害健康”。

本网网友:Curtain情歌
评论:做女孩一定要经的起谎言,爱的起敷衍,忍的了欺骗,忘得了诺言,放的下一切,最后用笑来伪装你的泪眼!

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin